Clinical Trials Browser

Hodgkin Disease, Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT05070104 2023-09-13

CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Phase 1 Withdrawn

C04.588.274.476.411.307

NCT02232152 2023-08-07

CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

19 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01835041 2023-07-12

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 1 Completed

21 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04593758 2023-05-24

To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Phase 1/2 Completed

16 enrolled

Sarcoma

Sarcoma, Clear Cell

NCT05733000 2023-03-10

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Phase 2 Recruiting

94 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma of Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03504410 2023-02-08

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

Phase 3 Terminated

200 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Phase 3 Completed

528 enrolled 11 charts

Gastrointestinal

Pancreatic Cancer Metastatic

NCT01766219 2019-05-15

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 1/2 Completed

17 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Carcinoma, Hepatocellular

NCT01839981 2018-12-27

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 1 Completed

10 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT03370159 2018-08-01

CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01768897 2018-07-03

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

67 enrolled

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT01931787 2018-07-03

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 1 Completed

15 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT01034475 2018-07-02

Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies

Phase 1 Completed

26 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02168907 2018-07-02

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1 Terminated

1 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

NCT03435289 2018-02-19

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

Phase 1 Unknown

24 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00907166 2017-03-21

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

Phase 1/2 Terminated

6 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT00741403 2016-12-29

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Phase 1 Completed

39 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT01520805 2016-12-29

Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT01832857 2016-12-29

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

Phase 2 Terminated

7 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT01830322 2013-08-14

Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer

Phase 2 Withdrawn

Tumor-Agnostic

Adenocarcinoma, Neoplasm Metastasis, Neoplasms